Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Current Assets: 2022-2024

Historic Current Assets for Axsome Therapeutics (AXSM) over the last 3 years, with Dec 2024 value amounting to $485.1 million.

  • Axsome Therapeutics' Current Assets rose 18.00% to $565.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $565.3 million, marking a year-over-year increase of 18.00%. This contributed to the annual value of $485.1 million for FY2024, which is 3.81% down from last year.
  • Axsome Therapeutics' Current Assets amounted to $485.1 million in FY2024, which was down 3.81% from $504.3 million recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Current Assets ranged from a high of $504.3 million in FY2023 and a low of $245.6 million during FY2022.
  • Over the past 3 years, Axsome Therapeutics' median Current Assets value was $485.1 million (recorded in 2024), while the average stood at $411.7 million.
  • Per our database at Business Quant, Axsome Therapeutics' Current Assets skyrocketed by 105.28% in 2023 and then declined by 3.81% in 2024.
  • Over the past 3 years, Axsome Therapeutics' Current Assets (Yearly) stood at $245.6 million in 2022, then spiked by 105.28% to $504.3 million in 2023, then fell by 3.81% to $485.1 million in 2024.